Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 12.15
- Piotroski Score 5.00
- Grade Outperform
- Symbol (NTRA)
- Company Natera, Inc.
- Price $124.34
- Changes Percentage (0.73%)
- Change $0.9
- Day Low $122.09
- Day High $125.26
- Year High $133.54
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is based in Austin, Texas.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/11/2024
- Fiscal Year End N/A
- Average Stock Price Target $125.00
- High Stock Price Target $150.00
- Low Stock Price Target $54.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$3.11
- Trailing P/E Ratio -35.75
- Forward P/E Ratio -35.75
- P/E Growth -35.75
- Net Income $-434,801,000
Income Statement
Quarterly
Annual
Latest News of NTRA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Are payment deferrals the new big thing in NHL contracts? What execs, agents say
NHL players like Jake McCabe are increasingly using deferred salary contracts to maximize earnings and provide teams with cap flexibility. While this trend may not become widespread due to player pref...
By The New York Times | 13 hours ago -
Union ends strike, 'Happy election day! Boeing workers have a contract!'
Boeing's unionized machinists voted to approve a new contract after a seven-week strike, allowing production to resume. The deal includes significant wage increases, bonuses, and job protections, mark...
By Newsweek | 13 hours ago -
The Fed tries to stay above politics. But a lot is at stake for the central bank on Election Day.
Yahoo Finance is analyzing key economic decisions that will face the next president in 2024. The Federal Reserve and Chairman Jerome Powell's future are at stake, with potential changes in monetary po...
By Yahoo! Finance | 14 hours ago
